AGEN - アジェナス (Agenus Inc.) アジェナス

 AGENのチャート


 AGENの企業情報

symbol AGEN
会社名 Agenus Inc (アジェナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジェナス(Agenus Inc.)は免疫腫瘍学(I-O)会社である。同社は癌と戦うために身体の免疫システムに関わる治療法の発見と開発に従事する。同社は、ヒト抗体を産生するように設計されたレトロサイトディスプレイ、SECANT酵母ディスプレイおよびファージディスプレイ技術を含む抗体発見プラットフォーム、チェックポイントモジュレーター(CPM)プログラムを含む抗体候補プログラム、並びにProphage、AutoSynVax、PhosPhoSynVax及びQS-21スチムロンアジュバント(QS-21スチムロン)を主とするサポニンベースのワクチンアジュバントを含むワクチンプログラムなどのプラットフォームとプログラムによって駆動されるI-Oポートフォリオを開発している。同社の発見パイプラインには、一連のチェックポイント変調(CPM)抗体が含まれる。ワクチンプラットフォームには、その熱ショックタンパク質(HSP)ベースのプロファージワクチン候補、およびその合成ワクチン候補のASVとPSVが含まれる。   アジェナスは米国のバイオ医薬品メ―カ―。主に、がん治療を目的に、免疫システム機能を調節するチェックポイント調節因子を標的とした抗体医薬品の発見、開発、商用化に従事。脳腫瘍、腎臓がん、肺がん、アルツハイマ―などの免疫治療用ワクチンの研究を行う。本社はマサチュ―セッツ州。   Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
本社所在地 3 Forbes Road Lexington MA 02421 USA
代表者氏名 Garo H. Armen ガロ・アーメン
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 781-674-4410
設立年月日 1994年
市場名 NASDAQ Small Cap
ipoyear 2000年
従業員数 255人
url www.agenusbio.com
nasdaq_url https://www.nasdaq.com/symbol/agen
adr_tso
EBITDA EBITDA(百万ドル) -113.91800
終値(lastsale) 2.07
時価総額(marketcap) 234493980.12
時価総額 時価総額(百万ドル) 223.16580
売上高 売上高(百万ドル) 29.24434
企業価値(EV) 企業価値(EV)(百万ドル) 193.05562
当期純利益 当期純利益(百万ドル) -150.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agenus Inc revenues decreased 44% to $17.5M. Net loss applicable to common stockholders increased 61% to $78.9M. Revenues reflect Revenue (research and development) decrease of 61% to $12.1M. Higher net loss reflects Non-operating income (expense) decrease from $2.4M (income) to $1.4M (expense) GENERAL AND ADMINISTRATIVE increase of 23% to $16.3M (expense).

 AGENのテクニカル分析


 AGENのニュース

   Investors Buy Large Volume of Call Options on Agenus (NASDAQ:AGEN)  2020/10/19 17:12:43 Transcript Daily
Agenus Inc. (NASDAQ:AGEN) saw unusually large options trading on Monday. Stock traders acquired 5,879 call options on the company. This represents an increase of approximately 310% compared to the average daily volume of 1,433 call options. AGEN has been the subject of a number of recent research reports. Jefferies Financial Group boosted their target price […]
   The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review  2020/09/11 12:05:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reacted to results for the half-year) Burning Rock Biotech Ltd (NASDAQ: BNR ) Evofem Biosciences Inc (NASDAQ: EVFM ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) ( reacted to a negative late-stage clinical readout for investigational migraine drug) Stocks In Focus Roche Presents Positive Long-Term Data For Multiple Sclerosis Drug Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) announced …
   Paul Clark Joins Agenus Board of Directors  2020/08/31 12:00:00 PR Newswire
LEXINGTON, Mass., Aug. 31, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of…
   Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China  2020/06/22 11:00:00 PR Newswire
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to…
   Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference  2020/06/17 15:06:00 PR Newswire
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc…
   Paul Clark Joins Agenus Board of Directors  2020/08/31 12:00:00 PR Newswire
LEXINGTON, Mass., Aug. 31, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of…
   Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China  2020/06/22 11:00:00 PR Newswire
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to…
   Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference  2020/06/17 15:06:00 PR Newswire
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc…
   Agenus to Present at the Raymond James Virtual Human Health Innovation Conference  2020/06/17 14:53:00 PR Newswire
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of…
   Agenus Announces Virtual Annual Shareholders Meeting  2020/06/16 12:12:00 PR Newswire
LEXINGTON, Mass., June 16, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually…
   Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China  2020/06/22 11:00:00 PR Newswire
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to…
   Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference  2020/06/17 15:06:00 PR Newswire
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc…
   Agenus to Present at the Raymond James Virtual Human Health Innovation Conference  2020/06/17 14:53:00 PR Newswire
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of…
   Agenus Announces Virtual Annual Shareholders Meeting  2020/06/16 12:12:00 PR Newswire
LEXINGTON, Mass., June 16, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually…
   Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?  2020/06/06 15:31:42 Zacks Investment Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジェナス AGEN Agenus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)